CSL | Jotup

Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options

Retrieved on:

Dienstag, Januar 16, 2024

KING OF PRUSSIA, Pa., Jan. 16, 2024 /PRNewswire/ -- CSL Behring, a business unit of global biotechnology leader CSL, today announced survey results showing that the majority of surveyed people living with chronic inflammatory demyelinating polyneuropathy (CIDP) agree they are interested in exploring more convenient treatment options (n=98, 82%) and that administering treatment at home is extremely/very important to them (n=100, 72%). However, less than half of people surveyed said they discuss potential new treatment options or switching treatments with a physician (n=100, 47% and 43% respectively). The CSL Behring-sponsored Harris Poll survey included 100 people living with CIDP, 98 of whom were currently on treatment for their CIDP, and 100 neurologists/neuromuscular specialists who regularly see at least one patient with CIDP.

Key Points:

However, less than half of people surveyed said they discuss potential new treatment options or switching treatments with a physician (n=100, 47% and 43% respectively).
The CSL Behring-sponsored Harris Poll survey included 100 people living with CIDP, 98 of whom were currently on treatment for their CIDP, and 100 neurologists/neuromuscular specialists who regularly see at least one patient with CIDP.
Additionally, less than half of patients surveyed said they are very/somewhat knowledgeable about how different CIDP treatment options work (40%) or about how different CIDP treatment options are administered (45%).
"We are proud to be at the forefront of delivering both effective and convenient treatment options like Hizentra, which may allow those living with CIDP more flexibility by allowing them to self-administer their treatment at home.

CSL LAUNCHES VOICELINK: THE 4G VoLTE COMMUNICATOR FOR LIFT ALARMS & EMERGENCY LINES

Retrieved on:

Dienstag, Januar 9, 2024

PSTN, Voice over IP, Sea, Digital transformation, Voice over LTE, CSL, ISDN, Hospital, Human voice, Cable television

LONDON, Jan. 9, 2024 /PRNewswire/ -- CSL, Critical IoT Connectivity experts, announce the launch of VoiceLink, the 4G VoLTE communicator for lift alarms and emergency lines.

Key Points:

LONDON, Jan. 9, 2024 /PRNewswire/ -- CSL, Critical IoT Connectivity experts, announce the launch of VoiceLink, the 4G VoLTE communicator for lift alarms and emergency lines.
VoiceLink allows voice calls to made via 4G VoLTE, ensuring installed systems are future-proofed and can continue to communicate correctly.
This new solution is ideal for lift alarms, found across retail, local councils, hospitals, and business premises.
It can also upgrade emergency phone lines that are present in many high-risk environments such as motorways, national grid sites, and petrol forecourts.

CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe

Retrieved on:

Mittwoch, Januar 3, 2024

PI, Travel, Immunoglobulin therapy, Learning, Physician, Disease, CIDP, Primary immunodeficiency, Therapy, CSL, The Harris Poll, CSL Behring, Patient, Skin, Senior, Vaccine

KING OF PRUSSIA, Pa., Jan. 3, 2024 /PRNewswire/ -- CSL Behring, a business unit of global biotechnology leader CSL, today announced the availability of a 10g prefilled syringe for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid). The Hizentra prefilled syringes provide people living with Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) the ability to elevate their treatment experience by eliminating the need to draw medication from vials. CSL Behring now has a wide range of prefilled syringe sizes to help meet the individual needs of people living with PI or CIDP including a 1g, 2g, 5g and 10g.

Key Points:

CSL Behring now has a wide range of prefilled syringe sizes to help meet the individual needs of people living with PI or CIDP including a 1g, 2g, 5g and 10g.
Hizentra offers the convenience of at-home infusions under the skin for individuals managing PI or CIDP.
"The availability of the 10g prefilled syringe is CSL Behring's latest development in helping the rare disease community effectively manage PI and CIDP, as some patients may require treatment at a higher volume," said Bob Lojewski, Senior Vice President and General Manager, North America, CSL Behring.
The availability of a 10g prefilled syringe comes at a time when people living with PI and CIDP seek more convenient treatment options.

CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials

Retrieved on:

Dienstag, Januar 2, 2024

Pillar, Marketing, CSL Behring, Patient, CSL, Vaccine

KING OF PRUSSIA, Pa., Jan. 2, 2024 /PRNewswire/ -- CSL Behring, a business unit of global biotechnology leader CSL, today announced the availability of 4- and 5-gram vial sizes for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]. Previously available only in a 1-gram vial, the 4- and 5-gram packaging is significant for the Alpha-1 community as it will streamline the preparation process for ZEMAIRA and reduce waste.

Key Points:

Previously available only in a 1-gram vial, the 4- and 5-gram packaging is significant for the Alpha-1 community as it will streamline the preparation process for ZEMAIRA and reduce waste.
ZEMAIRA dosing is weight-based, so a person weighing 183 pounds would require five 1-gram vials.
With the 4- and 5-gram vial sizes, healthcare professionals will need to reconstitute fewer ZEMAIRA vials per dose for their patients with Alpha-1.
Room temperature storage coupled with the larger vial sizes may also help streamline preparation and administration.

CSL and Adbri Partner to Build First Fully Electric Battery Capable Self-Unloading Ship

Retrieved on:

Mittwoch, Dezember 20, 2023

Partnership, DWT, CSL, Adbri, Canada Steamship Lines, Carbon, Steel, Cement

MONTREAL, Dec. 20, 2023 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, is excited to announce a 20-year strategic partnership with Adelaide Brighton Cement Ltd. (“Adbri”) to build and operate the world’s first fully electric battery capable self-unloading vessel.

Key Points:

MONTREAL, Dec. 20, 2023 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, is excited to announce a 20-year strategic partnership with Adelaide Brighton Cement Ltd. (“Adbri”) to build and operate the world’s first fully electric battery capable self-unloading vessel.
The custom-designed ship will replace Adbri’s Accolade II and will support the company's limestone operations in South Australia with a focus on enhanced efficiency and environmental responsibility.
The ship will carry up to 2.7 million tonnes of limestone per year, which represents a 35% increase over the existing vessel’s carrying capacity.
“Adbri is excited to have one of the world’s first 100% battery electric capable cargo vessels as our limestone carrier,” said Mark Irwin, Adbri Chief Executive Officer.

Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

Retrieved on:

Dienstag, Dezember 12, 2023

MF59, Fever, Șaeș, RSV, Aes, Respiratory syncytial virus, Vaccine, Human, Ageing, Lance, Vaccination, Myalgia, CSL, VLP, Safety, Infection

SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults.

Key Points:

“We’re delighted to announce positive topline interim data from our Phase 2 trial of IVX-A12, our potential first-in-class combination vaccine candidate against RSV and hMPV,” said Adam Simpson, Chief Executive Officer of Icosavax.
The trial enrolled 264 healthy older adults aged 60 to 85 years, of which 241 subjects were evaluable for immunogenicity.
Topline interim safety and immunogenicity data from this trial were generally consistent with the previously reported Phase 1 data for IVX-A12.
IVX-A12 induced robust immune responses against both RSV and hMPV at Day 28 across both formulations with and without adjuvant.

CSL Leads Maritime Industry in Biofuel Adoption, Achieving Milestones in Decarbonization Efforts

Retrieved on:

Freitag, Dezember 8, 2023

NOx, Sulfur oxide, International Council, Government, GHG, International Maritime Organization, Original equipment manufacturer, Ship, CSL, CIMAC, Canada Steamship Lines, Carbon, Organization, Steel, CO2, B80

MONTREAL, Dec. 08, 2023 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, proudly announces a significant milestone in its Great Lakes biofuel program – one of the longest-running initiatives of its kind in the maritime industry.

Key Points:

MONTREAL, Dec. 08, 2023 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, proudly announces a significant milestone in its Great Lakes biofuel program – one of the longest-running initiatives of its kind in the maritime industry.
With a cumulative 75,000 running hours on B100 biofuel over the past four years, CSL ships have made significant strides in supporting decarbonization efforts by replacing 55,000 metric tonnes of fossil fuel with biodiesel and avoiding 156,000 metric tonnes of CO2.
“Biofuel offers a practical and low-risk solution toward a decarbonized marine industry, but we need government support to ensure it remains affordable.
CSL is proud to lead the way in showcasing the effectiveness of biofuel, and we call on governments and industry stakeholders to accelerate the adoption of sustainable practices in maritime transportation.”
Since 2019, CSL’s biofuel program has played a pivotal role in shaping industry standards.

CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

Retrieved on:

Donnerstag, Dezember 21, 2023

ARCT-154 results were achieved with one sixth the dose of Comirnaty® (5 μg vs 30 μg).

Key Points:

ARCT-154 results were achieved with one sixth the dose of Comirnaty® (5 μg vs 30 μg).
The study was conducted in partnership with Meiji Seika Pharma, a global health company based in Japan.
The primary objective was to demonstrate immunological non-inferiority of ARCT-154 to Comirnaty®, as measured by neutralizing antibodies against Wuhan-Hu-1 SARS-CoV-2.
Key secondary objectives included the assessment of immunological non-inferiority and superiority against the Omicron BA.4/5 subvariant and vaccine tolerability assessed using participant-completed electronic diaries.

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

Retrieved on:

Donnerstag, Dezember 21, 2023

KING OF PRUSSIA, Pa. and SAN DIEGO, Dec. 21, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA (sa-mRNA) vaccine, elicited a numerically higher immune response (meeting the non-inferiority criteria) against the original Wuhan-Hu-1 virus strain, and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty®. ARCT-154 results were achieved with one-sixth the dose of Comirnaty® (5 μg vs 30 μg).

Key Points:

Both vaccines were well-tolerated, with no causally associated severe or serious adverse events.
The study was conducted in partnership with Meiji Seika Pharma, a global health company based in Japan.
"This study represents the first phase of CSL and Arcturus' plans to launch this innovative vaccine platform globally."
Key secondary objectives included the assessment of immunological non-inferiority and superiority against the Omicron BA.4/5 subvariant and vaccine tolerability assessed using participant-completed electronic diaries.

Cara Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on:

Montag, November 13, 2023

– Conference call today at 4:30 p.m. EST –

Key Points:

– Conference call today at 4:30 p.m. EST –
STAMFORD, Conn., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the third quarter ended September 30, 2023.
“We are pleased to have closed our non-dilutive financing transaction with HealthCare Royalty, which extends our cash runway into 2025,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics.
Wholesalers shipped 90,828 vials to dialysis centers during the third quarter of 2023.
Revenues: Total revenue was $4.9 million and $10.8 million for the three months ended September 30, 2023 and 2022, respectively.